Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.

开始日期2023-06-09

申办/合作机构

University of Southern California

[+2]

NCT06141356

/ RecruitingN/AIIT

[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease

[18F]Florbetazine ([18F]92) is a molecularly targeted imaging agent for Aβ protein with a novel diaryl-azine scaffold. It has shown specific binding affinity to Aβ aggregates in postmortem human AD brains and excellent brain pharmacokinetic properties with little non-specific retention in white matter in animal studies and a limited number of patients with Alzheimer's Disease (AD).
The purpose of the current study is to examine the binding properties of [18F]Florbetazine in human subjects and to compare the cortical and white matter binding with [11C]PiB or [18F]Florbetapir in the same subjects.
Imaging of the brain will be completed in healthy adult normal control participants and participants with cognitive impairment (including probable AD and dementia due to other conditions) to characterize [18F]Florbetazine uptake in the brain and its binding properties. [11C]PIB or [18F]Florbetapir PET imaging along with MRI will be completed in the same participants and the data will be compared with 18F-[18F]Florbetazine.

开始日期2023-01-30

申办/合作机构

北京协和医院

EUCTR2022-002585-33-IT

/ Not yet recruiting临床3期IIT

A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) - PETAL

开始日期2023-01-19

申办/合作机构

Fondazione Toscana Gabriele Monasterio

100 项与氟[¹⁸F]贝他苯相关的临床结果

登录后查看更多信息

100 项与氟[¹⁸F]贝他苯相关的转化医学

登录后查看更多信息

100 项与氟[¹⁸F]贝他苯相关的专利（医药）

登录后查看更多信息

221

项与氟[¹⁸F]贝他苯相关的文献（医药）

2025-04-01·Journal of Alzheimer’s Disease

Synergistic associations of amyloid-β and phosphorylated tau with tau aggregation and cognitive decline in Alzheimer's disease

Article

作者: Zhang, Chunhua ; Ba, Maowen ; Jia, Pengyuan ; Kong, Min ; Ma, Guozhao ; Tai, Yaojun

BackgroundThe pathological hallmarks of Alzheimer's disease (AD) include the amyloid-β (Aβ) plaques and phosphorylated tau (p-tau) forming neurofibrillary tangles. Understanding the pathophysiological cascade related to Aβ and tau process is crucial.ObjectiveTo investigate the impact of Aβ positron emission tomography (PET) and cerebrospinal fluid (CSF) p-tau on tau pathology and cognitive decline in AD.Methods We analyzed 319 older individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI) who underwent Aβ ( 18 F-florbetapir or 18 F-florbetaben) and tau ( 18 F-flortaucipir) PET scans, along with CSF and cognitive assessments. Aβ positivity (A+) was determined by global standardized uptake value ratio thresholds of ≥1.11 for 18 F-florbetapir or ≥1.08 for 18 F-florbetaben, while p-tau positivity (T+) was defined as CSF p-tau181 levels ≥23 pg/ml. Linear mixed regression models were used to assess the effects of PET Aβ and CSF p-tau181 levels on tau accumulation in predefined Braak regions and cognitive function over time. ResultsOur results revealed significant differences in PET tau pathology and cognitive decline between A + and A− individuals. We observed that interactions between Aβ and p-tau proteins were associated with tau accumulation and cognitive decline. Additionally, A−/T + individuals exhibited higher levels of tau accumulation in all Braak regions compared to A−/T− counterparts, suggesting a potential independent role of p-tau in tau pathology in the absence of Aβ.ConclusionsOur findings suggest that Aβ positivity and elevated CSF p-tau181 levels were associated with tau accumulation and cognitive decline, highlighting the relevance of soluble p-tau as a potential biomarker for further investigation.

2025-03-01·European Journal of Medicinal Chemistry

Progress in the study of anti-Alzheimer's disease activity of pyrimidine-containing bioactive molecules

Review

作者: Ma, Li-Ying ; Chui, Rui-Hao ; Zhang, Qi ; Zhang, Qian ; Li, Bing-Qian ; Zhang, Di ; Liu, Yu-Lin ; Zhang, Lin-Lin

Pyrimidines are aromatic, heterocyclic organic compounds characterized by a six-membered ring that contains four carbon atoms and two nitrogen atoms. They have been reported to exhibit a variety of biological activities such as antifungal, antiviral, and anti-Parkinsonian effects. Recently, there has been an increased focus on their potential anti-Alzheimer's properties. Several pyrimidine-based drugs and their analogs are currently undergoing various phases of clinical trials, indicating pyrimidine as a promising chemical structure for drug development. Notably, modifications to the pyrimidine structure significantly influence their activity against Alzheimer's disease. For instance, the introduction of heteroatoms into the pyrimidine ring or alternations in the length of the linkage region have been shown to enhance therapeutic efficacy. This review provides a comprehensive overview of pyrimidine derivatives as potential therapeutics for Alzheimer's disease, with a focus on structure-activity relationship (SAR) studies, design strategies, and binding mechanisms. These insights could pave the way for the development of more effective anti-Alzheimer's medications.

2024-12-01·Alzheimer's & Dementia

Unusually young onset of spastic paraparesis in a carrier of both the A431E PSEN1 and A713T APP variants

Article

作者: Ringman, John M ; Islas, Miguel Angel Macias ; Villareal, Enrique Israel Velazquez ; Sheikh‐Bahaei, Nasim ; Craig, David

AbstractBackgroundThe ways in which diverse genetic variants interact to affect the phenotype of AD is poorly understood. The relatively consistent phenotype associated with specific mutations causing autosomal dominant AD (ADAD) provides the opportunity to study how other genetic variants contribute to disease manifestations.MethodWe performed an in‐depth case study of a patient with the A431E PSEN1 mutation who had onset of progressive spastic paraplegia at age 20.ResultThe proband was a Mexican woman known to be at 50% risk for inheriting the A431E PSEN1 mutation that commonly presents with cognitive changes and/or spastic paraplegia at age 40. At age 20 she began developing stiffness in her legs and difficulty walking. When seen at age 26 she had diffuse spasticity worse in the legs, slurred speech, and was cognitively intact. A flortaucipir PET scan at the time was negative as was a florbetaben scan 21 months later despite marked differences from controls in DTI measures in the corticospinal tract. Genetic screening demonstrated the presence of the A431E PSEN1 mutation and an A713T APP variant which was confirmed by WGS. The A713T APP variant was not present in her mother who had more typical disease nor in 62 other persons of Mexican origin.ConclusionThe A713T variant in APP has been shown to affect APP processing and Abeta nucleation and is considered to be a risk factor for AD. We hypothesize that the presence of this variant led to the early onset of spastic paraparesis in our proband despite Abeta deposition in brain being undetectable on PET. This finding suggests spastic paraplegia may be related to aberrant APP processing in a manner distinct from plaque formation.This study was funded by R01AG062007 and R01AG069013

项与氟[¹⁸F]贝他苯相关的新闻（医药）

2025-04-24

·PRNewswire

Life Molecular Imaging announces Neuraceq® availability at PharmaLogic Salt Lake City

Enhanced the supply capabilities of Neuraceq® to increase patient access to beta-amyloid PET imaging BOSTON, April 24, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI) and PharmaLogic Holdings Corp. (PharmaLogic), a world-class contract development and manufacturing organization (CDMO) and radiopharmacy solutions provider, announce the expansion of their strategic partnership and licensing agreement to produce and distribute Neuraceq® from PharmaLogic's PET radiopharmaceutical manufacturing facility located near Salt Lake City, Utah. The first commercial doses were made available on April 23, 2025. Continue Reading Neuraceq® is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs, or for enrollment in clinical trials to further support drug development in neurodegenerative diseases. Enhanced the supply capabilities of Neuraceq® to increase patient access to beta-amyloid PET imaging. Post this "Life Molecular Imaging is pleased to expand the availability of Neuraceq® to Salt Lake City, enhancing access for patients and imaging centers in this key region. This expansion reflects LMI's commitment to ensuring broad accessibility to Neuraceq®, reinforcing our dedication to supporting a key step on the pathway to treatment," said Colleen Ruby, US Country Head and Chief Operating Officer, Americas and APAC. About Neuraceq (florbetaben 18F) Indication Neuraceq® is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations. Limitations of Use A positive Neuraceq® scan does not establish the diagnosis of AD or any other cognitive disorder. Safety and effectiveness of Neuraceq have not been established for: Predicting development of dementia or other neurologic conditions Monitoring responses to therapies. Important Safety Information Risk for Image Interpretation and Other Errors Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation. Image interpretation should be performed independently of the patient's clinical information. The use of clinical information in the interpretation of Neuraceq images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future. Radiation Risk Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure. Common Adverse Reactions The overall safety profile of Neuraceq is based on data from 1,090 administrations of Neuraceq to 872 subjects. No serious adverse reactions related to Neuraceq administration have been reported. The most frequently observed adverse drug reactions in subjects receiving Neuraceq were injection site reactions consisting of erythema (1.7%), irritation (1.1%) and pain (3.4%). For more information please visit: neuraceq.com About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI) is an international pharma company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit . About Life Healthcare Group Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 40 years' experience in the South African private healthcare sector, and currently operates 64 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, oncology, diagnostic and molecular imaging and health risk management services which include occupational health and wellness services. The Group also owns Life Molecular Imaging, a radiopharmaceutical business dedicated to developing and globally commercializing innovative molecular imaging agents for use in PET-CT diagnostics to detect specific diseases. Visit: | For media queries Brittany Hahn | Marketing Communications Manager | Life Molecular Imaging Tel: +1.484.735.2840 | [email protected] SOURCE Life Molecular Imaging WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

引进/卖出

2025-03-28

·先通医药

全新诊断时代 |氟[18F]贝他苯注射液助力阿尔茨海默病早期、精准、无创诊断

点蓝色字关注“先通医药”记忆，是时光编织的书卷，每一页都浸染着生命的温度；也是人生故事的载体，每一道波纹都镌刻着独一无二的故事。然而，阿尔茨海默病（AD）正在无声地夺走无数家庭的温暖回忆。▲欧韦宁®产品图为了帮助医生和患者早期发现、精准诊断、及时干预阿尔茨海默病，先通医药持续践行“做好核药，惠及大众”的使命，历经多年努力，成功推出我国首个且唯一获得国家药品监督管理局批准的淀粉样蛋白PET（amyloid-PET，Aβ-PET）显像剂——氟[18F]贝他苯注射液。氟[18F]贝他苯注射液用于脑正电子发射断层扫描（PET）显像，测定AD及其他认知功能下降成年患者脑内β-淀粉样蛋白（Aβ）神经炎性斑块的水平1。截至2025年1月，氟[18F]贝他苯注射液已在京津冀鲁等地区实现商业化供货。氟[18F]贝他苯注射液填补了我国AD诊断活体金标准的空白，为广大医疗工作者提供了可靠、有效的诊断手段，帮助患者更早、更准确地识别病情，抓住干预治疗的宝贵时机。让我们从产品的基本信息开始，进一步了解这款创新诊断工具的更多细节。基本信息1中文通用名称：氟[18F]贝他苯注射液中文商标名：欧韦宁®英文通用名：Florbetaben [18F] Injection（缩写FBB）英文商品名：Neuraceq®曾用名称：18F-AV1活性成分：氟[18F]贝他苯，放射性核素为氟[18F]有效期：自合成结束时间（EOS）起 10 小时内有效批准文号：国药准字H20234130适应症1本品是一种用于脑正电子发射断层扫描（PET）显像的放射性诊断药，应用于测定阿尔茨海默病 (AD) 和其他认知功能下降成年患者脑内β-淀粉样蛋白神经炎性斑块的水平。通过测定脑内Aβ斑块水平，用于AD精准诊断、鉴别诊断及疗效评估。适用范围21.疑似AD，出现认知障碍/痴呆典型或不典型症状者，不限年龄；2.由专科医师评估可接受Aβ单抗治疗，和监测Aβ单抗疗效效果者；3.脑脊液（CSF）生物标志物状态可疑，待明确的患者；4.不愿意行腰椎穿刺术脑脊液检测AD生物标志物理患者；5.存在高AD风险（年龄、基因、家族史）的主观认知障碍患者。药品特点：精准、早期、无创●欧韦宁®是国家标准GMP生产、质控高，国内首个获批用于阿尔茨海默病诊断的Aβ-PET显像剂，显像更稳定准确，促进阿尔茨海默病精准诊断和治疗3-4●亲和力、灵敏度高，显像噪声小，图像质量更高，阅片一致性和准确性高可视化稳定显示脑内Aβ斑块分布可定量评估Aβ斑块负荷5-10●《2024美国阿尔茨海默病学会（AA）诊断和分期标准修订版》《2024国际工作组（IWG）推荐：AD临床-生物学架构》《2018中国痴呆与认知障碍诊治指南》《中国阿尔茨海默病痴呆诊疗指南（2020年版）》等权威指南一致推荐：Aβ-PET用于AD早期诊疗11-15●Aβ-PET是AD核心生物标志物11，是AD早期启动Aβ单抗治疗和效果评估的重要手段16●可在痴呆症状出现前15～20年，识别Aβ斑块病理变化4,17●Aβ-PET检测手段无创且适用度高，避免有创过程引起的不适和并发症11用法用量1本品推荐剂量为300MBq（8.1mCi），最大化学剂量为30μg，通过单次缓慢静脉推注给药（6秒/ml），注射体积最大不超过10ml。注射前需检查是否含有颗粒物质，如有则不应使用。为避免局部外渗导致辐射以及成像伪影，用药前注射生理盐水确认留置套管通畅，注射后用约10ml生理盐水冲洗。Aβ-PET检查无需空腹，无需禁食，无需禁水，无需视听封闭。根据患者状况，如果必须注射镇静剂使用，需要神经内科、精神科等临床科室评估，并做出镇静剂处方，并尽可能在显像剂后注射，保证上机扫描时起效。阅片方法1阅片方法是比较大脑皮层灰质与邻近白质中的显像剂摄取程度。应确定PET图像中显示的解剖位置对应于白质结构（如小脑白质或胼胝体压部）区域，以帮助阅片人定位。图像应以系统的方法判读和评估，从小脑开始，移动到外侧颞叶、额叶、后扣带回/楔前叶、顶叶。皮层灰质区域的大多数断层受累，才能被评估为存在“显像剂摄取”。对于每位患者，PET图像评估被归类为“β-淀粉样蛋白阳性”或“β-淀粉样蛋白阴性”，该判读基于以下4个大脑区域中的灰质显像剂摄取：颞叶、额叶、后扣带回/楔前叶、顶叶。 β-淀粉样蛋白阴性：所有4个大脑区域中灰质显像剂摄取（即信号强度）均低于白质（无β-淀粉样蛋白沉积）。β-淀粉样蛋白阳性：4个大脑区域中至少1个出现灰质显像剂摄取较小面积等同或高于白质，扩展越过白质边界到达外皮质边缘，涉及大多数断层。▲阴性（上排）和阳性（下排）PET 显像的横断面图像图注释：小脑：在阴性和阳性图像中均可见白质（箭头）和灰质之间的差异。可以观察到头皮和后矢状窦（箭头尖）中的脑外显像剂摄取。外侧颞叶：在阴性图像中可见白质（箭头）的“刺状”或“山状”外观，并且，由于灰质中的显像剂摄取较低，放射性信号不会到达大脑外缘（虚线）。而由于灰质中的显像剂摄取，阳性图像显示出脑实质外缘（虚线）的“饱满”、光滑外观。额叶：在阴性图像中可见额叶中白质（箭头）的“刺状”外观。阳性图像显示，由于灰质信号增加，这些区域中的显像剂摄取具有“饱满”、光滑的外观（虚线）。后扣带回/楔前叶：胼胝体压部（箭头）附近和后方的区域在阴性图像中显示为低强度“孔”（圆圈），而这个孔在阳性图像中被“填满”（圆圈）。顶叶：在阴性图像中，可以很容易地识别顶叶之间的中线（长箭头）；白质具有刺状外观（短箭头），在大脑外缘（虚线）附近的信号较低。而在阳性图像中，顶叶之间的中线相较不容易识别；由于显像剂摄取延伸到大脑的外缘，皮质区域被“填满”并且显示出光滑的外观。研发和临床应用历程2017年：先通医药获得中国独家研发、注册申请及商业化权利。2019—2021年：完成中国桥接临床试验，最终于2023年9月获国家药监局（NMPA）批准。2025年：1月8日已在京津冀鲁等地使用。循证证据：有效性、安全性1.有效性诊断效能：氟[18F]贝他苯Ⅲ临床试验结果显示，以尸检为参考标准，氟[18F]贝他苯脑PET显像检测效能良好，视觉阅片检测AD脑内Aβ沉积的灵敏度高达98%，特异度为89%。182.真实世界研究：美国多中心、大型真实世界IDEAS研究显示，既往常规诊断方法72.4%临床医生对AD患者诊断信心不足，使用淀粉样蛋白PET显像（包含氟[18F]贝他苯）后，诊断信心不足的比例下降到16.2%，其临床应用可显著提高AD诊断的准确性和医生的信心。193.安全性：无给药相关的严重不良反应报告。受试者中观察到的最常见的药物不良反应为注射部位红斑、刺激、疼痛。所有不良反应均为轻至中度，且持续时间短1。早诊早治，守护记忆之光氟[18F]贝他苯注射液的上市，为临床医生与患者提供了早期、精准且无创的AD诊断新工具。作为中国放射性药物领域的新生代力量，先通医药将继续深化创新核医学诊断技术的研发与应用，积极推动该产品在全国范围内的临床普及，助力更多医疗机构与患者及时、准确地识别疾病征兆，及早采取科学干预措施。让我们共同努力，点亮记忆守护之光，温暖千万家庭。▌参考文献1. 氟[18F]贝他苯注射液说明书.2. Rabinovici GD, et al. Alzheimers Dement. 2025 Jan;21(1):e14338.3. Pontecorvo MJ, et al. JAMA Neurol. 2022 Dec 1;79(12):1250-1259.4. Jack CR Jr, et al. Lancet Neurol. 2010 Jan;9(1):119-28.5. Arakawa Y, et al. J Nucl Med. 2017 Aug;58(8):1285-1292.6. Sabri O, et al. Alzheimers Dement. 2015 Aug;11(8):964-74.7. Clark CM, et al. Lancet Neurol. 2012 Aug;11(8):669-78.8. Rowe CC, et al. Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2053-2059.9. Navitsky M, et al. Alzheimers Dement. 2018 Dec;14(12):1565-1571.10. Bischof GN, et al. J Nucl Med. 2021 Jul 1;62(7):999-1005.11. Jack CR Jr, et al. Alzheimers Dement. 2024 Aug;20(8):5143-5169.12. Dubois B, et al. JAMA Neurol. 2024 Dec 1;81(12):1304-1311.13. 中国痴呆与认知障碍写作组, 等. 中华医学杂志,2018,98(13):971-977.14. 国家卫生健康委办公厅. 全科医学临床与教育,2021,19(1):4-6.15. 中华医学会神经病学分会痴呆与认知障碍学组, 中华医学会核医学分会. 中华医学杂志, 2023, 103(45): 3615-3626.16. van Dyck CH, et al. N Engl J Med. 2023 Jan 5;388(1):9-21.17. Long JM, et al. Cell. 2019 Oct 3;179(2):312-339.18. Rabinovici GD, et al. JAMA. 2019 Apr 2;321(13):1286-1294. 19. Sabri O, et al. Alzheimers Dement. 2015 Aug;11(8):964-74. *滑动查看本文披露内容仅作为学术交流之目的，在任何情况下均不得被视为医疗建议。我司对所有原创、转载、分享的内容的准确性、完整性或时效性不做任何陈述或保证。文中所涉数据仅供参考，不能视为建议或推荐，以及要约或邀请。本材料以公开信息、内部开发的数据和来自其它具有可信度的第三方的信息为基础。但是，并不保证这些信息的完全可靠。所有的观点和看法基于材料撰写当日的判断，并随时有可能在不予通知的情况下进行调整。本文提及的任何药品，我司不对其在诊疗活动中的性能、临床表现等做任何承诺及保证。END关于先通医药先通医药是中国创新放射性药物领域的领先企业，专注于放射性药物的研发创新及落地应用以改善患者的健康水平。先通医药于2014年正式开展新一代放射性药物的研发，总部位于北京，在上海设有研发中心，在江苏、广东、四川建设有现代化放射性药物智能生产基地；同时，在美国设有分支机构，并与十几家跨国药企达成战略合作。全球放射性药物主要应用于神经、心血管、肿瘤三大疾病领域，先通医药已实现全面布局，并拥有20+精准诊断和靶向治疗放射性药物研发管线。凭借自身的研发优势，先通医药获得了投资机构的青睐，2020年4月至今，已成功募资超20亿元人民币，未来不久将登陆主要资本市场，成为中国放射性药物领域的创新力量。

诊断试剂

2025-03-24

·医药健闻

跨国药企在中国 | 阿斯利康、礼来、诺华、美敦力、武田制药、飞利浦、贝克曼库尔特、辉瑞、杰特贝林、勃林格殷格翰、罗氏等新动态

跨国药企在中国重点资讯文 | 苏丁企业动态阿斯利康阿斯利康(AstraZeneca)3月21日宣布25亿美元投资计划，在北京建立第六个全球战略研发中心，并达成多项重大研发与生产合作，以进一步推动中国生命科学事业发展。这项未来五年的投资计划是阿斯利康与北京市人民政府和北京经济技术开发区管理委员会战略合作伙伴关系的一部分，它同时还包括了公司与和铂医药、元思生肽、康泰生物三家生物科技企业达成的合作协议，以及近期宣布的珐博进中国收购协议。通过这一系列部署，阿斯利康预计在北京的员工人数将增至1700人。礼来礼来中国宣布其首个创新加速平台——礼来北京创新孵化器投入运营，是礼来在全球设立的第四家同类机构。礼来创新孵化器致力于助力早期生物科技企业成长，孵化器内配备了一流的即用型实验室、共享会议室以及便捷的工作站点等办公设施。孵化器预计能够容纳5家至8家生物科技企业及其团队入驻，为其提供成长所需的物理空间与配套设施。诺华 3月23日至24日，中国发展高层论坛2025年年会在京举行。诺华首席执行官万思瀚(Vasant Narasimhan)受邀参会，围绕医药领域前沿创新及协作等议题展开研讨，这也是万思瀚第七次参加这一盛会。同期，他还出席了第六届国际医药创新大会。诺华围绕“大健康产业高质量发展”议题，分享了“创新与协作”两大核心理念的实践路径，并介绍了在放射配体疗法这一前沿领域取得的突破性进展。美敦力中国发展高层论坛2025年年会在北京举行，美敦力董事长兼首席执行官杰夫·马萨在年会期间表示，美敦力坚信中国将成为全球最大的医疗市场和重要的创新策源地，也将成为医疗创新、投资与合作的战略枢纽。他表示，美敦力是首批进入中国的跨国医疗科技企业之一。目前，美敦力在中国拥有约6000名员工、12个区域办公室，构建了研发、生产、销售、培训、售后和投资基金的全价值链布局，包括1个研发中心、2个创新中心和5大生产基地。武田制药武田制药董事长、总裁、首席执行官卫博科在中国发展高层论坛2025年年会表示，中国已经成为了全球第二大医药市场。伴随着经济发展和人口增长，潜在的医疗健康需求也在持续增加。卫博科说，“近期，我们与成都市政府达成战略合作协议，建立武田中国创新中心（TCIC）。这一数字化创新中心将拓展我们的数字创新战略蓝图，赋能武田更好地为患者提供高质量的服务。” 飞利浦《河南商报》报道，飞利浦（中国）投资有限公司河南分公司注册成立并已取得营业执照，郑州航空港生物医药大健康产业再添强劲动力引擎。飞利浦是世界知名的健康科技公司，在诊断影像、图像引导治疗、病人监护等多个领域处于全球领先地位。贝克曼库尔特3月21日-24日，第二十二届中国国际检验医学暨输血仪器试剂博览会（CACLP）在杭州举行。丹纳赫携旗下包括贝克曼库尔特在内的10余家运营公司再次以集团形式亮相，展台总面积达396平米。贝克曼库尔特推出全新DxAI智医报告解读工具。该工具深度融合DeepSeek、Kimi和豆包等先进的大语言模型（LLM），以智能化的数据分析和解读能力，为临床检验决策提供强有力的支持，助力精准诊疗。DxAI的应用不仅提升了检验结果的可解释性和决策效率，更推动了医疗AI向更高效、更精准的方向发展，为智慧医疗开辟了全新可能。贝克曼库尔特“肿瘤标志物实验室检测高质量发展”专题论坛也在同期举办，与专家学者、行业同仁共同探讨新医疗模式下肿瘤标志物的挑战与机遇。辉瑞辉瑞中国宣布了一项重要的领导层与组织架构调整。现任肿瘤事业部总经理王玉女士决定寻求新的职业发展机会，李进晖女士将接任肿瘤及罕见病事业部总经理一职。此外，辉瑞中国对组织架构进行了优化，决定将零售业务团队和全国招标团队与原商务团队合并，成立商务与零售部。曹智被任命为新成立的商务与零售部负责人，直接向辉瑞中国区总裁汇报。杰特贝林杰特贝林亚太区副总裁兼总经理Jean-Marc Morange向员工宣布，来自辉瑞的王玉被任命为杰特贝林中国大陆和香港地区总经理，自4月2日起履新。基于Veeva China CRM Suite打造的C360 Elite数字化运营平台已在杰特贝林中国（CSL Behring）成功上线，将助力杰特贝林实现客户管理、学术推广及运营策略的全链路数字化升级。此次上线的C360 Elite平台基于Veeva China CRM Suite构建，在满足中国市场合规要求的同时，通过智能化数据洞察与合规化流程设计，赋能一线团队精准触达医疗专业人士（HCP）的学术需求，优化患者服务生态。科赴中国健康促进与教育协会自我健康管理分会3月14日正式在京成立。科赴中国率先就推进“自我健康管理”与协会签署战略合作备忘录，就积极支持协会开展科普传播、探索建立协作机制、促进能力提升、加强相关研究等相关工作与协会达成共识，并将共同致力于推动公众健康素养水平和“自我健康管理”能力的提升。上海德达医院 3月14日，上海德达医院正式获得由上海市卫生健康委员会颁发的医疗机构执业许可证，成为全国首家外商独资心血管专科医院。上海德达医院于2016年9月在青浦区徐泾镇开业，并于2018年入选上海首批高水平社会办医机构。2024年4月，太古股份有限公司(集团)宣布，已完成增持德达医疗股份的交易。太古集团最初于2021年对德达医疗进行联属投资，并于2024年3月签署最终协议以增持其股份。产业动态辽宁省肿瘤医院暨大连理工大学附属肿瘤医院与罗氏正式签署合作协议，将共同致力于肺癌全程管理数字化解决方案的建设。此次合作旨在应对肺癌这一全球癌症难题，聚焦肺癌围手术期精准治疗，通过智能化数字平台打通诊疗全流程，助力提升患者诊疗体验、生存质量和康复效果，造福更多中国患者。勃林格殷格翰与广州金苗动保科技有限公司达成战略合作，将利用金苗动保的多联多价载体疫苗技术为动物防护多种疾病。勃林格殷格翰将依托自身全球研发网络，与金苗动保紧密协作，优化疫苗种子构建环节，缩短研发周期，推动创新疫苗研发进程。通过公司在动物保健领域的首个“在中国，为全球”研发合作，勃林格殷格翰致力于加速动物疫苗研发进程。在第七届动物医院院长大会上，勃林格殷格翰正式宣布，其进口原研宠物治疗药物圣咪乐（猫用替米沙坦内服溶液）上市，进一步推动猫慢性肾病（CKD）诊疗发展。作为全球首个宠物用血管紧张素受体阻断剂（ARB），圣咪乐用于治疗猫CKD引起的蛋白尿，自2013年全球首次上市以来已帮助无数CKD患猫改善生活质量。CKD是老年猫最常见的慢性疾病之一，发病率高达30%，15岁以上的猫咪患病比例更是接近80%。 Life Molecular Imaging（LMI）和St. Teresa's Hospital宣布，Florbetaben（18F）注入液（Neuraceq）将于2025年3月从St. Teresa's Hospital在中国香港上市。Neuraceq有望在早期和准确诊断阿尔茨海默病(AD)方面发挥重要作用，并提高香港对AD的认识。联系美通社 +86-10-5953 9500 info@prnasia.com

并购放射疗法抗体药物偶联物

100 项与氟[¹⁸F]贝他苯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	氟[¹⁸F]贝他苯	V09AX06	DB09148

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
认知功能障碍	挪威	Life Molecular Imaging Ltd.	2014-02-20
认知功能障碍	列支敦士登	Life Molecular Imaging Ltd.	2014-02-20
认知功能障碍	冰岛	Life Molecular Imaging Ltd.	2014-02-20
认知功能障碍	欧盟	Life Molecular Imaging Ltd.	2014-02-20
诊断试剂	列支敦士登	Life Molecular Imaging Ltd.	2014-02-20
诊断试剂	欧盟	Life Molecular Imaging Ltd.	2014-02-20
诊断试剂	挪威	Life Molecular Imaging Ltd.	2014-02-20
诊断试剂	冰岛	Life Molecular Imaging Ltd.	2014-02-20
阿尔茨海默症	加拿大	Isologic Innovative Radiopharmaceuticals Ltd.	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
免疫球蛋白轻链淀粉样变性	临床3期	西班牙	Life Molecular Imaging Ltd.	2023-01-13
阿尔茨海默症	临床2期	法国	Life Molecular Imaging Ltd.	2009-11-01
阿尔茨海默症	临床2期	日本	Life Molecular Imaging Ltd.	2009-11-01
阿尔茨海默症	临床2期	澳大利亚	Life Molecular Imaging Ltd.	2009-11-01
阿尔茨海默症	临床2期	德国	Life Molecular Imaging Ltd.	2009-11-01
脑淀粉样血管病	临床2期	日本	Life Molecular Imaging Ltd.	2009-11-01
脑淀粉样血管病	临床2期	法国	Life Molecular Imaging Ltd.	2009-11-01
脑淀粉样血管病	临床2期	美国	Life Molecular Imaging Ltd.	2009-11-01
脑淀粉样血管病	临床2期	德国	Life Molecular Imaging Ltd.	2009-11-01
脑淀粉样血管病	临床2期	澳大利亚	Life Molecular Imaging Ltd.	2009-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02831283 (CTgov)	临床2期	阿尔茨海默症 \| 炎症	60	11C-PBR28+18F-Florbetaben (Amyloid-positive With Cognitive Impairment (AD))	簾膚夢憲壓願淵鹹構廠(憲廠鑰獵鹽願蓋鹹憲襯) = 鹽餘觸遞齋積淵鑰構願獵糧鑰製醖網膚範衊觸 (觸窪憲獵鏇繭蓋範糧夢, 壓製顧網構觸製醖遞夢 ~ 憲鑰製範窪齋鏇築艱繭) 更多	-	2025-03-05
				11C-PBR28+18F-Florbetaben (Amyloid-positive Without Impairment (Preclinical AD))	簾膚夢憲壓願淵鹹構廠(憲廠鑰獵鹽願蓋鹹憲襯) = 觸觸繭範簾構積艱觸積獵糧鑰製醖網膚範衊觸 (觸窪憲獵鏇繭蓋範糧夢, 淵餘醖鏇簾艱壓鏇憲膚 ~ 窪淵遞淵憲構鹹獵簾網) 更多
NCT01222351 (CTgov)	N/A	阿尔茨海默症 \| 认知功能障碍	161	BAY 94-9172 (Florbetaben)	艱醖鬱憲艱襯鹹艱鑰膚(衊簾淵憲衊壓壓鏇齋糧) = 遞鏇鹽鹽齋製願夢鏇觸製壓構膚鏇膚獵壓窪鏇 (製築構齋遞繭糧憲願淵, 憲醖鏇鬱膚憲顧選鬱蓋 ~ 網繭衊鬱醖積衊膚糧膚) 更多	-	2024-05-06
NCT03744312 (CTgov)	临床1/2期	阿尔茨海默症 \| 炎症	9	Florbetaben+11C-ER176 (Cognitive Impairment)	艱壓膚製鑰夢積淵鹽齋(鬱窪衊築醖範鹹簾選獵) = 淵觸廠鏇獵顧觸鏇獵鹹艱顧鏇鏇壓衊範積襯築 (鏇築積獵鬱獵襯積簾築, 憲艱憲顧鬱窪淵積夢憲 ~ 壓選襯簾襯衊廠鬱築鏇) 更多	-	2023-09-13
				Florbetaben+11C-ER176 (No Cognitive Impairment)	艱壓膚製鑰夢積淵鹽齋(鬱窪衊築醖範鹹簾選獵) = 襯簾餘範齋鹽製簾構淵艱顧鏇鏇壓衊範積襯築 (鏇築積獵鬱獵襯積簾築, 簾齋憲範積壓鏇窪壓餘 ~ 積窪築齋窪糧選積夢網) 更多
AMYPAD Diagnostic and Patient Management Study (EANM2022)	N/A	记忆障碍 amyloid burden	729	18f-florbetaben (FBB)	願衊鑰廠範顧願顧襯顧(築鏇醖膚醖窪鹽膚醖鏇) = 構觸襯淵網網顧醖鹽鑰繭糧淵選憲範願築壓構 (鑰淵膚淵醖願遞淵選鑰, 17.87) 更多	-	2022-09-22
				18f-flutemetamol (FTM)	願衊鑰廠範顧願顧襯顧(築鏇醖膚醖窪鹽膚醖鏇) = 觸餘鹹鏇築繭遞淵齋齋繭糧淵選憲範願築壓構 (鑰淵膚淵醖願遞淵選鑰, 17.87) 更多
EANM2021	N/A	淀粉样蛋白斑 \| 牙周炎	-	18 F-Florbetaben (Absence of periodontal disease or mild periodontitis)	糧壓鏇鏇鹹觸簾鹽選顧(醖蓋窪夢獵鑰憲製範憲) = 齋鹹淵獵構襯遞醖餘衊蓋鏇窪顧醖醖蓋鬱遞艱 (選遞醖鬱膚遞憲選壓鹽 )	-	2021-09-24
SNMMI2020	N/A	淀粉样蛋白斑	-	18 F-Florbetaben (Young Healthy Controls (YHC))	憲網獵淵夢糧築餘衊憲(蓋蓋鑰遞衊糧糧艱壓蓋) = 餘齋積構廠鏇鹹網壓願積廠齋簾願選襯衊製顧 (壓蓋積選願網網夢壓淵, 0.03)	-	2020-05-15
				18 F-Florbetaben (Subjective Cognitive Decline (SCD))	夢窪鑰鬱範鏇範積醖簾(繭獵製廠築糧製觸簾觸) = 獵衊壓簾觸獵壓廠憲顧鏇餘衊醖觸齋簾遞鏇構 (廠構齋蓋構膚膚鏇糧壓, 2.1) 更多
EANM2019	N/A	过氧物酶体病 gene defect \| very long chain fatty acids (VLVFA)	4	[18F]Florbetaben (X-linked adulthood cerebral adrenoleukodystrophy (X-ACALD) patients)	淵築醖鬱憲鬱憲鑰淵獵(鏇膚鏇醖製糧夢夢鬱艱) = 9.8 ± 2.6 簾淵積獵築蓋夢鏇選鬱 (襯鬱選夢鏇觸夢艱艱淵 ) 更多	-	2019-09-18
				[18F]Florbetaben (Healthy control group)
EANM2019	N/A	-	6	[18F]Florbetaben (Standard PET images)	壓範範網廠廠窪遞餘醖(鏇壓範衊觸積廠夢衊範) = 遞網齋觸膚鹽廠鬱鏇遞醖鑰鑰蓋鑰鏇鏇鹹膚遞 (積膚顧遞願築鏇餘築鹽 ) 更多	-	2019-09-18
				[18F]Florbetaben (PET images with superimposed WM/GM boundaries)	(醖築繭鏇遞餘築網顧廠) = 齋壓壓餘繭選廠糧廠範築簾選淵鹹製構築艱鹽 (淵願鏇壓鹹鏇醖網窪蓋 ) 更多
EANM2018	N/A	-	44	18F-Florbetaben (Amyloid-PET)	醖艱築鬱鏇餘壓觸齋願(鏇醖鹽齋鹽鹹鹹醖壓壓) = 範鬱膚鑰鏇獵鹹衊夢選鹽範構餘觸鏇願蓋鏇蓋 (鏇網醖鏇膚獵蓋夢繭網 )	积极	2018-09-18
AAIC2018	N/A	轻度痴呆 \| 轻度认知障碍 ApolipoproteinE (APOE) genotype	152	[F-18] FLORBETABEN (Cognitively Normal)	繭鏇糧鹹鬱願繭淵齋衊(夢築夢膚積願壓窪壓憲) = 鬱選遞襯襯獵鏇糧襯餘觸繭鏇夢鏇範鹽簾淵積 (窪糧襯鹽窪齋蓋醖窪醖 )	-	2018-07-01
				[F-18] FLORBETABEN (Mild Cognitive Impairment)	繭鏇糧鹹鬱願繭淵齋衊(夢築夢膚積願壓窪壓憲) = 鑰鑰壓觸壓範鏇簾構衊觸繭鏇夢鏇範鹽簾淵積 (窪糧襯鹽窪齋蓋醖窪醖 )